IMiD treatment
PreclinicalSmall molecule
Bristol-Myers SquibbIMiD treatment is one of 51 small molecule programs targeting Lymphoma. It is currently in Preclinical.
2
Indications
3
Total Trials
2
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Zofran
NovartisPreclinical
Norvir
AbbViePreclinical
Wellcovorin
GGlaxo Dba Glaxosmithkline
Preclinical
Tafasitamab
IncytePreclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
CAR-T
HHebei Senlang Biotechnology Inc., Ltd.
Preclinical
Rhg-CSF
CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Preclinical
VP-16
FFundamenta Therapeutics, Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Multiple Myeloma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IMiD treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company